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Abstract 
Glaucoma presents considerable challenges in providing clinically and cost-effective care 
pathways.  While UK population screening is not seen as justifiable, arrangements for case 
finding have historically been considered relatively ineffective.  Detection challenges include 
an undetected disease burden, whether from populations failing to access services or 
difficulties in delivering effective case-finding strategies, and a high false positive rate from 
referrals via traditional case finding pathways.  The enhanced General Ophthalmic Service 
(GOS) in Scotland and locally commissioned glaucoma referral filtering services (GRFS) 
elsewhere have undoubtedly reduced false positive referrals, and there is emerging 
evidence of effectiveness of these pathways.  At the same time, it is recognised that 
implementing GRFS does not intrinsically reduce the burden of undetected glaucoma and 
late presentation, and obvious challenges remain.  In terms of diagnosis and monitoring, 
considerable growth in capacity remains essential, and non-medical health care professional 
(HCP) co-management and virtual clinics continue to be important solutions in offering 
requisite capacity.  National guidelines, commissioning recommendations, and the Common 
Clinical Competency Framework have clarified requirements for such services, including 
recommendations on training and accreditation of HCPs.  At the same time, the nature of 
consultant-delivered care and expectations on the glaucoma specialist’s role has evolved 
alongside these developments. Despite progress in recent decades, given projected capacity 
requirements, further care pathways innovations appear mandated.  While the timeline for 
implementing potential artificial intelligence innovations in streamlining care pathways is far 
from established, the glaucoma burden presents an expectation that such developments 
will need to be at the vanguard of future developments. 
 
Introduction 
The Royal College of Ophthalmologists (RCOphth) commissioned ‘The Way Forward’ project 
given an increased awareness of the growing number of patients with ophthalmic diseases 
of older age across the UK without a commensurate growth in the number of 
ophthalmologists and other human or financial resources available to treat those patients1.  
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This scenario is illustrated by the comparative statistic that a decade ago there were ~4.9 
million UK residents over 75 years of age, whereas by 2035 the population over 75 years is 
expected to be more than 80% larger at 8.9 million2, with this growth in the elderly 
population precipitating increased demand for glaucoma care.  The Way Forward project’s 
modelling1 predicts the number of people in the UK with glaucoma will increase by 22% 
from 2015 to 2025 and by 44% from 2015 to 2035, with the report conceding that this 
growth might underestimate demand in a scenario where improved detection and 
management may result in more prevalent cases converting to diagnosed cases requiring 
ongoing management.  With glaucoma management currently being responsible for an 
estimated 20% of Hospital Eye Service (HES) ophthalmology out-patient workload, the 
previously coined term the ‘bow wave of doom’, a once apt metaphor for the growing 
demand for glaucoma care resulting from lifelong follow-up requirement in spite of low 
incidence, now understates what might be better considered to reflect a burgeoning tidal 
wave of demand.  It is prescient therefore to have a review article re-examining glaucoma 
care pathways as part of this feature issue. 
 
This review will focus on eye care services in care pathways relating to glaucoma detection 
and referral as well as diagnosis and management of glaucoma (and glaucoma related) 
diagnoses, and including those services falling within both primary care and secondary care 
settings.  For the purposes of this review, models of care will be considered broadly in 
reference to the way health services are delivered, outlining the evidence base for care for a 
person, population group or patient cohort, in this case those at risk of glaucoma and those 
with a diagnosis of glaucoma.  The care pathway, i.e. setting out the process of best practice 
to be followed in management of glaucoma, reflects a distillation of the best available 
evidence on care processes.  For convenience we will consider separately the care pathways 
for case finding and referral filtering on the one hand, and for monitoring on the other, 
while recognising that the actual diagnosis of glaucoma and related monitoring services may 
take place in a variety of clinic environments.  In setting out this review, it also needs to be 
borne in mind that the four countries of the UK have different structures and eye care 
services.  With decisions on health being devolved, Northern Ireland, Scotland and Wales 
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can make their own decisions in relation to health; however, this review will not explicitly 
seek to present separate analyses of the care pathways employed (indeed, arguably the 
countries’ systems themselves are reliant on the same evidence base), rather it will 
highlight, where applicable, relevant similarities and differences. 
 
Our searches broadened upon and updated an earlier published review3 which included 
relevant electronic databases (MEDLINE, EMBASE, Cochrane Library, and Health 
Management Information Consortium (HMIC), Cumulative Index to Nursing and Allied 
Health Literature (CINAHL) and PsycINFO) and appropriate grey literature (e.g. websites, 
professional publications, and national guidelines). Keywords for bibliographic searches 
included the condition specific term glaucoma, profession-specific terms (optometrist, 
ophthalmic optician, orthoptist, nurse and ophthalmologist), and care pathway related 
terms (enhanced services, shared care, co-management, virtual clinic, delegated care, and 
referral filtering and refinement).  
 
Glaucoma detection pathways 
Background 
Community optometry services for opportunistic ‘case finding’ for glaucoma in the UK are 
largely provided under the General Ophthalmic Services (GOS), with contracts being held 
between the NHS and optometry practice owners or contractors.  Most ‘sight tests’ 
conducted in England, Northern Ireland and Wales (and all tests in Scotland) are under a 
GOS contract, free to the patient at the point of delivery, and from which the vast majority 
of referrals for suspected glaucoma have traditionally been initiated.  In England, there are a 
number of eligible groups for NHS funded sight tests, including those with or who may be at 
higher risk of developing glaucoma: those aged over 60; those diagnosed with glaucoma; 
those aged 40 and over where a close family member (parent, sibling or child) has been 
diagnosed with glaucoma; and those considered at risk of glaucoma by an ophthalmologist.  
In Northern Ireland and Wales, NHS funded sight test eligibility from a glaucoma risk 
perspective is very similar, with the GOS being managed, respectively, through the Health 
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and Social Care Board and NHS Wales.  In Scotland, NHS eye tests were extended to the 
entire population in 2006.  
 
Glaucoma referral filtering schemes (GRFS) 
As distinct from the GOS and related arrangements for NHS sight tests commissioned 
nationally, in England primary eye care services (previously known as enhanced services) 
may be commissioned by individual Clinical Commissioning Groups (CCGs) and provide a 
mechanism for enhancements to an NHS sight test or private eye examination.  These 
services include what are now termed glaucoma referral filtering schemes (GRFS), schemes 
which refer to: glaucoma repeat measures schemes (GRMS); glaucoma enhanced referral 
schemes (GERS); and glaucoma referral refinement schemes (GRRS).  The NICE Quality 
Standard (QS180)4 and Glaucoma Guideline update (NG81)5, provide statements and 
recommendations for people planning and providing eye care services before referral such 
that they should consider commissioning referral filtering services for Chronic Open Angle 
Glaucoma (COAG) and related conditions.   
 
In essence, GRFSs can be considered to be hierarchical in terms of the extent of 
accreditation and additional case finding or diagnostic testing required ahead of referral.  In 
accordance with the NICE Glaucoma Guideline5, the NICE Quality Standard4 and the NICE 
Accredited RCOphth Commissioning Guideline6, GRMS involves repeating intra-ocular 
pressure (IOP) measurement and/or visual fields, and is mostly undertaken by optometrists 
without additional accreditation beyond entry level, GERS adds value beyond repeat 
measures (e.g. dilated stereoscopic optic disc examination) and is undertaken by clinicians 
with the College of Optometrists’ (CoO) Professional Certificate in Glaucoma or equivalent, 
and finally GRRS includes tests sufficient for a diagnosis (i.e. by definition a scheme which 
must also include gonioscopy) and is undertaken by those accredited to the Professional 
Higher Certificate in Glaucoma (previously Certificate A, or the equivalent for non-
optometrists).  Being relevant to not only detection but also to monitoring pathways, the 
matter of non-medical training and accreditation for glaucoma roles within the care 
pathways (including GRFS) is reviewed separately in more detail below. 
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An example of a published GERS pathway7 is illustrated in figure 1. The Manchester scheme 
includes: symptoms and history evaluation; evaluation of general health, medications, 
previous eye history and family history; evaluation of glaucoma risk factors; visual acuities; 
anterior segment assessment; van Herick assessment of the angle; Goldmann applanation 
tonometry; pachymetry; visual field assessment; and a dilated fundus examination 
incorporating clinical optic disc assessment using slit-lamp biomicroscopy (with either a 78D, 
60D or 66D lens).  
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Figure 1: GERS care pathway example from the Manchester scheme (After Gunn et al, 
2018).  In the traditional model referral for suspect glaucoma is via the GP.  In the GERS 
pathway, the accredited optometrist, post examination, either makes a direct referral to 
Manchester Royal Eye Hospital (MREH) for specialist assessment or discharges the patient 
from the scheme. 
 
One cautionary point to note when considering the literature on GRFS, however, is the 
potential for various terms to be applied in different settings and at different time points. 
For example, true GRRSs appear to be few and far between (i.e. in the strict sense of the 
need for such services to include testing sufficient for a diagnosis of glaucoma and to be 
delivered by appropriately accredited practitioners in accordance with NICE); however, it is 
clear that the ‘referral refinement’ term was used historically for many years to describe 
some GRFSs before NICE guidance was published, for example the original Manchester 
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scheme8. Furthermore, the term referral refinement is still used to describe some GRFSs in 
other countries, for example, the Carmarthenshire GRRS, a scheme without inclusion of 
gonioscopy9, or in a jurisdiction where NICE does not apply, for example, the ‘referral 
refinement’ scheme described by Barrett et al10 in Ireland. 
 
GRFS have been in operation in the UK for almost two decades and Manchester’s GRRS, now 
termed the Manchester GERS to fit with the NICE definition, was the first such scheme to be 
established8.  The Way Forward report1 highlighted the national need for referral filtering 
and indicated that GRFS are widespread, with 66% (31/47) of glaucoma leads interviewed 
indicating referral filtering is in operation in their locality.  The GRMS category of referral 
filtering appears most widespread in England, with data from the Local Optical Support Unit 
(LOCSU) listing ~60 such schemes across Local Optical Committees in England11, in contrast 
to ~15 “glaucoma referral refinement” schemes in self-evidently far fewer regions, and 
where strictly speaking, as implied above, many of which are likely to be representative of 
the GERS model versus true GRRS as the term has now come to be defined.  From the 
stakeholder perspective, patients and others including commissioners appear to respond 
positively to these community services12,13. 
  
Effectiveness of traditional case finding and GRFS 
Community optometrists identify the vast majority of suspect glaucoma and ocular 
hypertension (OHT) cases in the UK through GOS sight testing14-17; however, without referral 
filtering (which at least in part works well through ‘enriching’ the target population of 
interest18) the false positive rate is considered to be high.  This latter finding appears to be 
so Europe-wide, with a recent study concluding that the accuracy of referrals is poor in the 
UK and other countries, and that a combination of criteria and raising the IOP threshold for 
IOP-only referrals are needed to cut waste in clinical care19. Early UK studies of referral for 
glaucoma by optometrists illustrated optometrists’ criteria for using “screening” tests and 
their subsequent decisions on the referral of suspects varied widely20-22.  Consequently the 
false positive rate from the traditional detection pathway through case finding has typically 
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been found to be high, for example, ranging from 20–65%20,21,23-27.. Vernon and Gosh28 
established that the provision of specific referral guidelines, circulated to all optometrists 
working within the catchment area, had little effect upon false referrals.  It was against this 
background that referral refinement was introduced and an early evaluation of this first 
GRFS, the Manchester GRRS, observed a reduction in the FP rate from ~40% to ~10%8.  
Subsequently, Ratnarajan et al29 published the first multisite review of GRFS in the UK, using 
a timeline encompassing all the major changes in clinical guidelines and practice following 
the publication of the original NICE guideline (CG85)30 and including a sample of over 1000 
patient outcomes in a retrospective observational time series study.  Their findings showed 
a significant impact on the false positive rate, with the first-visit discharge rate for 
optometrists with a specialist interest (i.e. GRFS participants) being significantly lower at 
14.1% compared with 36.1% for those optometrists not GRFS accredited29.  There are fewer 
studies evaluating the false negative rate within community GRFS.  One study in 
Carmathanshire9 included a retrospective analysis of 100 sets of notes and optic nerve 
images of patients not referred through the scheme. The authors quoted a FN rate of 3-10% 
and concluded their findings indicated ‘no compromise on patient safety’9.  Ratnarajan et 
al31 included consultant clinical review of non-referred patients, albeit on only a limited 
sample of 34 discharged subjects willing to attend the hospital for review, and concluded 
that the false negative rate of the optometrists in their scheme was 15%, although no cases 
of glaucoma were missed.  More recently, the largest study of the false negative rate of a 
GRFS was published using a methodology where a proportion of non-referred study patients 
were all examined in the same NICE aligned clinic model as that for usual care referred 
patients7.  The findings showed a low false negative rate, no clinical incidents associated 
with false negatives, and concluded that this GERS model was an effective GRFS.  
 
Effectiveness of the enhanced GOS model 
Outside of the locally commissioned arrangements for GRFSs in England, the enhanced GOS 
in Scotland also appears to offer an improvement over traditional case finding 
arrangements.  For example, in an early evaluation following the introduction of GOS 
changes in Scotland in 2006, Ang et al32 demonstrated an improvement in the quality of 
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glaucoma referrals from community optometrists in northeast Scotland, with a 
corresponding reduction in false positive referrals.  El-Assal et al33 retrospectively reviewed 
hospital glaucoma clinic data from 1622 patients in two 6 year periods, one before the 
introduction of the new GOS contract, between 2000 and 2006, and the other after the 
contract was introduced, between 2007 and 2012.  They reported that patients were now 
being referred earlier, with shorter waiting times for hospital appointments, and with 
referrals comprising more glaucomatous cases and fewer false positives. Since then, SIGN 
144 (Glaucoma referral and safe discharge)34 has been published and this too appears to 
have afforded a further improvement in referral accuracy. In a retrospective study, Sii et al35 
observed a significant decline in the first visit discharge rate when comparing two 2-month 
periods both before (29.2% first visit discharge rate) and after (19.2% first visit discharge 
rate ) the publication of SIGN 144, while also observing room for improved adherence to 
referral criteria.  On a more specific clinical query, Annoh et al36 recently examined the 
accuracy of referrals for primary angle closure related diagnoses in Scotland.  In 769 
consecutive referrals they determined that community optometrists had ‘good’ ability to 
detect eyes at risk of angle closure, with only 12% of those referred for possible angle 
closure being discharged at the first visit.  In Wales, the GRFS established in 
Carmarthenshire has been determined to be clinically effective, with a 53% reduction in 
referrals to the HES9.  In Northern Ireland, Black et al37 describe an audit comparing 
optometrists’ practice in assessing signs for glaucoma pre- and post-training and 
accreditation for working within a GRMS.  Participation in the scheme had a positive impact 
on practitioners’ choice of pre-referral assessments performed in primary care. 
 
Cost-effectiveness of GRFS 
In comparison to data on clinical effectiveness, there remains a paucity of data on the cost-
effectiveness of GRFS. In their realist review, Baker et al3 noted that cost savings from GRFS 
for suspected glaucoma are based on the number of HES referrals prevented versus the 
schemes’ costs. Using community optometrists with a specialist interest in glaucoma to filter 
referrals from other optometrists varies in cost-effectiveness from cost-neutral38 to 
producing a small8,39 or substantial9,40 saving compared to equivalent HES care. Cost-
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effectiveness appears to depend upon scheme activity and assumptions in the financial 
model.  Henson’s early evaluation of ‘referral refinement’8 certainly sparked reasonable 
questioning of such assumptions41,42. Interestingly, the introduction of a GRMS in South 
London (i.e. where the original referring community optometrists repeated tests to confirm 
abnormality prior to referral or non-referral to the HES) produced a 62% cost-saving 
compared to the usual HES tariff38.   Henson et al8, Devarajan et al9 and Parkins and Edgar38 
all based their financial analysis of GRFS on the assumption that more than one HES visit is 
required prior to discharge for false positive referrals.  Henson et al8 based their analysis on 
the assumption that false positive patients who would have attended the HES without a 
GRFS would have had on average 2.3 clinic visits before being discharged, a figure that is 
based on a review of new referrals to the MREH made before the introduction of the 
Manchester scheme. Devarajan et al9 also based their financial analysis on the assumption 
that a false positive referral would otherwise have an average of 2.3 clinic visits before 
discharge and Parkins and Edgar38 and Ratnarajan et al29,39 assumed an average of 2.1 visits 
prior to discharge.  A more recent study analysing the costs of the Manchester GERS43 
indicates that ~2.2 visits need to be avoided to make their scheme cost saving, albeit the 
authors also note that reducing the volume of referrals will reduce waiting time for an 
outpatient appointment and therefore GERS has the potential to reduce waiting times as 
well as false positive referrals.  One interesting innovation in the past decade is the use of a 
virtual clinic model (more typically used in monitoring schemes and discussed below) to 
refine40 and triage44 community referrals, with the former study in Portsmouth showing 11% 
of patients ‘attending’ virtual clinics being accepted into the HES, while releasing ~1400 
clinic slots per year to the local NHS Trust.  A further potential GRFS innovation is the use of 
technology.  For example, the GATE study45 compared optic nerve and nerve fibre layer 
imaging technologies for filtering referrals alongside VA and IOP data, and while showing 
cost effectiveness, the filtering resulted in 1 in 7 cases of glaucoma being inappropriately 
discharged; however, some form of automated referral filtering seems likely to be realised 
in the future as technology advances. 
 
Care pathways for glaucoma diagnosis and monitoring  
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The development of ‘shared care’ 
Shared care or co-management has come to represent the sharing of clinical management 
responsibilities between two or more health care professionals from different disciplines, 
although it is clear the term ‘shared care’ may mean different things to different people, for 
example: data collection only, data collection and decision making by protocol, and data 
collection and autonomous decision making.  Shared care may also include virtual clinic 
activity (see below).  In an early editorial on the topic of shared care, Hitchings46 welcomed 
the concept, while highlighting legitimate concerns about how such schemes might operate, 
particularly outside the confines of the hospital, and in an era pre-dating the evidence base 
now held on the effectiveness of non-medical health care professionals (HCP) working in 
glaucoma care.  The timeline chart in figure 2 illustrates factors that have promoted the 
development of non-medical HCP’s engagement in glaucoma shared care in the past 30 
years.  
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Figure 2: Timeline chart incorporating key legislation, guidelines, safety alerts and key 
professional developments in the three decades between 1989 and 2019.  The figure shows 
the wider context and enablers for progression of non-medical HCP’s engagement in 
glaucoma care pathways beyond those traditionally encountered in previous decades.  Key 
to acronyms: IP (independent prescribing); CoO (College of Optometrists); GRRS (Glaucoma 
Referral Refinement Scheme); GOC (General Optical Council); DoH (Department of Health); 
NICE (National Institute for Health Care and Excellence); NPSA (National Patient Safety 
Agency); GOS (General Ophthalmic Service); HQ (Higher Qualification); SIGN (Scottish 
Intercollegiate Guidelines Network); and CCC (Common Clinical Competency). 
 
A decade ago Vernon and Adair47 set out to determine the number and nature of shared 
care schemes for glaucoma and glaucoma suspects operating in England.  Their survey 
showed that even before the outcome of the then Department of Health shared care pilots 
had been published, approximately 50% of ophthalmic departments were running schemes 
for glaucoma; however, these authors concluded at the time that most schemes contributed 
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only modestly to the overall volume of glaucoma care, with the majority of glaucoma-
related consultations being undertaken by ophthalmologists.  This scenario has almost 
certainly changed in recent years. The Way Forward report1 noted 88% of glaucoma clinical 
leads interviewed had incorporated non ophthalmologists into expanded roles.  Harper et 
al48 published a comprehensive evaluation of the scope of practice of optometrists working 
in the UK HES.  Their results, with an excellent response rate of 70 of 79 survey invitations, 
described the substantial majority of respondents (96%) undertook “extended” clinical 
roles, with glaucoma being the leading extended role service provided by optometrists (92% 
of respondents providing extended role services).  In terms of the general scope of practice, 
this survey found evidence that optometrists engaged in these extended roles did so with a 
significant degree of autonomy, with only 23% of clinics being reported to ‘never go ahead’ 
without an ophthalmologist also being present. While the presence or absence of a 
consultant or other member of the medical team within the clinic does not necessarily mean 
that medical clinical decision support was unavailable, across all extended role services in 
general, less than a third of respondents replied that they ‘often’ or ‘always’ required 
consultation with medical colleagues, a response that was provided within the context of a 
senior optometrist experienced at working within the extended role, and not an optometrist 
in training for the role.  In Vernon and Adair’s survey47, the shared care staff members were 
able to prescribe medication for glaucoma in only 8 schemes (12%).  As will be evident from 
developments summarised in the timeline in figure 2, there is now a much changed 
scenario, not least in terms of the prescribing of therapeutics.  
 
In terms of effectiveness data, the first high quality evidence for the potential role of non-
medical HCPs in glaucoma monitoring was derived from the Bristol shared care glaucoma 
study. This randomised control trial (RCT) compared community optometry monitoring of 
stable glaucoma to routine care in the hospital glaucoma clinic, and determined that 
optometrists could take clinical measurements of comparable quality to usual care49,50 and 
that over the 2-year study period, there was no difference in patient outcomes between the 
two arms51. Since this RCT, there is further supportive evidence that specialist optometrists, 
when additionally trained and accredited in glaucoma, can make appropriate diagnostic and 
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clinical management decisions compared to a subspecialist ophthalmologist reference 
standard52-56.  In terms of community based co-management, other observational studies 
have concluded that with further glaucoma training, optometrists can be an acceptable 
alternative to hospital care for selected glaucoma patients and those at increased risk of 
glaucoma57-59.   
 
The literature on nursing roles in the glaucoma care pathway provides evidence of roles in 
patient education, including improving adherence, and in helping patients with sight loss, 
for example, Ney60.  It is also clear that nurse-led glaucoma clinics have been in existence for 
many years, for example Johnson et al61, including a role in glaucoma related laser 
procedures62; however, the authors are unaware of empirical studies evaluating nursing 
decision making performance in glaucoma versus, for example, studies reporting on the 
taking of specific clinical measurements (e.g. tonometry63).  Similarly, in the UK there does 
not yet appear to be orthoptic specific evidence for performance in glaucoma care roles, 
albeit it can be legitimately argued that the overall HCP evidence base affords evidence well 
beyond “proof of concept”, and as such the evidence available is likely to be applicable to 
any professional with appropriate training and accreditation and experience (a matter 
considered in more detail below).  Indeed, while conceding that nursing roles in the wider 
UK health care setting were inherently less independent than those of optometrists, The 
Way Forward report1 proposed that the Ophthalmic Common Clinical Competency 
Framework (OCCCF)64, discussed in context below, should help to ensure that a consistent 
level is achieved by all HCPs, regardless of professional grouping or starting point. 
 
Risk stratification in the glaucoma monitoring care pathway 
It is widely recognised that there is significant diversity of case complexity in glaucoma and 
glaucoma-related diagnoses, with potential vision related outcomes varying from minimal 
lifetime risk of sight loss through to significantly higher risk of either imminent or longer 
term sight-threatening glaucoma. This range in case complexity is reflected in 
commensurate variations in the care pathway required for glaucoma patients, and in the 
level of training and skills required by participating non-medical HCPs, now significantly to 
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the fore in dealing with the burden of glaucoma.  The RCOphth and the CoO have recently 
produced joint ophthalmic services guidance on primary eye care services, community 
ophthalmology and general ophthalmology65 and The Way Forward summary for glaucoma1 
describes stratification of patients’ risk of sight loss being used to organise review at virtual 
clinics, HCP specific clinics and consultant clinics, while also noting the importance of clarity 
for discharge policies for those referred with possible glaucoma (and found not to have it) or 
for OHT, and including the need for clear instructions for re-referral. 
 
Recent years have witnessed improvements in eye care services within the four home 
nations of the UK, with each country developing individualised pathways for delivery of eye 
care in line with government and local health service policies66, with public health 
promotion, improvement in provision and accessibility, and the use of a multidisciplinary 
model being seen as key5,6,34,67,68.   In England, the Clinical Council for Eye Health 
Commissioning has produced a system assurance framework for eye health, SAFE, (see 
figure 3), encouraging and supporting services in primary and secondary care to develop 
pathways involving suitably qualified HCPs to help with the increasing capacity and demand 
pressures69.  Of note here is an important reminder of the significance of the need for wider 
patient support elements within the pathway, including for example, the potential need for 
referral for low vision rehabilitation, for completion of the Certificate of Visual Impairment 
facilitating access to wider support and services, and for considering the risks of depression. 
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Figure 3: Clinical Council for Eye Health Commissioning (CCEHC) System and Assurance 
Framework for Eye-health (SAFE) Glaucoma Service System. 
 
From the perspective of the community setting, LOCSU11 in England has produced a 
glaucoma monitoring pathway for those patients considered suitable for community 
monitoring. 
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Figure 4: The Local Optical Support Unit (LOCSU) has developed an integrated service 
pathway made available to local optical committees and commissioners to consider as a tool 
for developing glaucoma care pathways for monitoring patients with glaucoma and related 
conditions in the community (after LOCSU, 2019). 
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Virtual clinics in glaucoma care 
Caring for people with glaucoma and related conditions is an enormous task requiring multi-
professional collaboration, discussed above, as well as innovations in service delivery.  One 
such innovation is the ‘virtual’ clinic.  In these models of care, some of which utilise 
electronic patient records (including web-based data recording), patient data is usually 
collected by technicians, ophthalmic nurses and/or non-specialist orthoptists or 
optometrists, with subsequent ‘virtual’ consultant ophthalmologist/expert clinician data 
review and decision making70,71. The care model is usually implemented for follow up 
attendances either in hospital or community clinic settings (including services that make use 
of a mobile clinic facility).  These clinics are intended to: maximise appointment capacity and 
reduce waiting times; provide a ‘one stop shop’ with all tests being performed on the day; 
and ensure that people who can be discharged are discharged sooner by consultant or 
expert clinician review.  Alternatively, and as noted above, the virtual model has been used 
to refine community referrals40.    
 
A recent survey by Gunn et al72 determined that glaucoma virtual clinics are employed by a 
large proportion of HES units, with many others seeking to develop such services.  Clinical 
leads largely rate efficiency, patient safety and the perception of patients’ acceptability to 
be at least equivalent to standard care.   The RCOphth Standards for Virtual Clinics in 
Glaucoma Care 73 aimed to define minimum standards for the development and 
implementation of virtual clinics for glaucoma in the secondary care setting and was 
produced by expert panel consensus. The document provides recommendations on patient 
suitability for virtual clinic monitoring, test procedures and processes, staffing, data 
collection and governance. The panel recommended that patients with OHT, suspected 
open angle glaucoma, or early or moderate glaucoma (open angle or pseudophakic patients 
with a history of angle closure) in the worse eye may be suitable for this type of clinic 
model.  Gunn et al’s survey findings suggest that most respondents were already working 
within these recommendations, with 90.5% using virtual clinics to assess patients with OHT 
and 71.4% assessing glaucoma suspects72. However, this survey did note that 28.6% of 
respondents included patients at any stage of disease, provided their condition was deemed 
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to be ‘stable’. The ‘Standards’ do allow for Consultant discretion in deciding on whom to 
refer to a virtual clinic, although they do recommend excluding patients who have non-
glaucomatous pathology.  In terms of safety, a study by Clarke et al74 showed that virtual 
clinics can be safe, with misclassification events at just 1.9%. Furthermore, Kotecha et al75 
and Court and Austin’s76 studies have shown that patients are accepting of virtual clinics 
under certain provisos, albeit these studies involved patients from a mainly Caucasian 
population with low risk eye disease and arguably further qualitative research is necessary 
to understand more about both different patient groups and clinicians’ experiences and 
perceptions of virtual clinics, to further inform approaches to this model of care. The Way 
Forward report highlighted familiar barriers to use of virtual clinics, raising clinicians’ 
concerns surrounding taking away the human, face-to-face element of decision-making1, 
although Gunn et al’s survey72 indicates that commonly reported barriers for clinicians 
relate to practical issues including having insufficient time, funding, staffing or space 
resources to establish and run virtual clinics, with clinical leads working in acute trusts or 
major teaching hospitals being more likely to have overcome these barriers. 
 
While not the same as a virtual clinic, the reviewing of cases awaiting future appointments is 
another option for evaluating the clinic backlog.  For example, in a recent study aptly titled 
‘tackling the NHS glaucoma clinic backlog issue’ Broadway and Tibbenham77 describe 
examining 9290 cases in a 3 year study evaluating whether previously planned clinic reviews 
were appropriate.  They concluded that departments experiencing significant backlog issues 
should consider using trained glaucoma sub-specialist consultants to review the planned 
follow up management of patients within a backlog deficit.  Other units have considered 
external providers to help with backlog issues, including the use of providers employing a 
virtual clinic model70.  The Way Forward report highlighted some advantages of such an 
approach while cautioning on the need for careful retention of patient data collected by 
outside providers in order to avoid clinical governance risks associated with loss of data and 
the potential adverse consequences to patient care1. 
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Consultant-delivered clinics 
Consultant-delivered clinics represent the conventional model of glaucoma care, with 
patients attending an ophthalmic outpatient clinic traditionally staffed by a team of junior 
and middle grade ophthalmologists led by a consultant. From a historical perspective, 
nurses would perform visual acuity assessment and ophthalmic technicians would have 
performed visual field testing and optic disc imaging. With the increasing demand upon 
glaucoma services outstripping capacity, newer models of service delivery have been 
developed as described above.  Nevertheless the conventional consultant delivered clinic 
continues to provide a vital role in glaucoma care:  
 
• Patients still require diagnoses to be consultant-led, and this requirement becomes 
particularly important for secondary glaucomas or other conditions which may 
mimic glaucomatous signs and symptoms, including other ocular or neurological 
disease.   
• Once glaucoma is diagnosed and treated, patients who do not respond to (or who 
cannot tolerate) first and second-line therapies require consideration of surgery or 
other interventions requiring consultant leadership.   
• Some patients have complex or multiple ocular co-morbidities which do not easily fit 
into the more protocol-driven shared care or virtual clinic models and require face-
to-face consultations. 
• Patients who have undergone glaucoma surgery need consultant-led review in the 
immediate post-operative period to ensure surgical success.  
 
Hence the case mix of consultant-delivered clinics has evolved from delivering care to all 
patients with glaucoma related conditions, to one which is predominantly reserved for 
moderate to high risk glaucoma cases. 
 
Personnel resourcing consultant-delivered clinics have also evolved over time. The 
development of shared care and virtual clinics and the extended clinical skills acquired by 
HCPs provides the opportunity for optometrists, nurses and orthoptists to become 
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integrated into consultant-delivered clinics, fulfilling the same roles as junior and middle-
grade ophthalmologists. The Way Forward report1 highlighted that this direct consultant 
supervision of HCPs provides a solution to meet capacity requirements, as well as providing 
an opportunity for teaching, training, and professional development of non-medical HCPs, a 
factor contributing to job satisfaction and retention of HCPs, and ensuring facilitation of 
increased autonomy in shared care clinics for lower risk cases without direct consultant 
supervision. 
 
Evolution of the Consultant role within the care pathway 
In the same way that the roles of non-medical HCPs have been extended to delivering 
glaucoma services47,48, the role of the consultant ophthalmologist has also evolved alongside 
the adoption of newer ways of working. Clinical assessment and management of individual 
patients remains a key role, although increasingly this role is confined to higher risk and 
more complex cases. Performing surgery and other interventional procedures also remains 
largely in the domain of ophthalmologists and led by consultants. Additionally consultants 
have always led the teaching and training of ophthalmologists and other HCPs. With the 
further development and expansion of the shared care and virtual clinic models, the 
demand of being a lead-trainer for HCPs has increased, whilst also retaining responsibilities 
for the teaching and training junior ophthalmologists. Furthermore, the role of ‘Clinical 
Lead’ for glaucoma services now demands not only the skills of the consultant to lead on the 
re-design of service models and the training and accreditation of HCPs, in addition to their 
own clinical responsibilities of outpatient and surgical sessions, but they also need to fulfil a 
governance role in oversight of these services and responsibility for the safety and 
effectiveness of these models of care. Whilst those HCPs with recognised higher 
qualifications may take full responsibility for the care they deliver, many HCPs fulfil their 
roles under supervision, directly or indirectly, by a consultant. The absolute numbers of 
patients who are registered to a named consultant may therefore steadily increase as an 
ophthalmic unit develops and expands newer models of care to meet increasing demand. 
Consultant ophthalmologists have always taken ultimate responsibility for patients seen and 
managed by ‘other members of the team’, however this team has moved from the confines 
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of consultant-delivered clinics, to separate HCP clinics, sometimes performed at times and 
locations remote from the consultants’ own clinics.  Overseeing quality of care may become 
increasingly difficult.  Furthermore, as many of these newer models of care are protocol 
driven and directed specifically to the detection and monitoring of only glaucoma 
conditions, the risk of other diagnoses going undetected increases. These potentially 
undiagnosed conditions may range from cases of mild dry eye or developing cataract, to 
unrecognised systemic side effects from glaucoma therapies, to other more serious non-
glaucomatous sight-threatening or systemic conditions, possibly associated with mortality. 
When consultant ophthalmologists have ultimate responsibility for the patients seen in 
these clinics, they also take on these associated risks. 
 
Whilst these risks can never be completely eliminated, consultant ophthalmologists who 
take responsibility for care delivered by other professionals need to consider what measures 
need to be put in place to minimise risk, and they must have confidence that the skills and 
knowledge of HCPs delivering care is to an appropriate level, given the degree of oversight 
possible by the consultant. Where possible HCPs should be encouraged and supported to 
obtain higher professional qualifications in order to practice autonomously and take full 
responsibility for the care they provide independently of the consultant, a matter 
considered separately below5,64. 
 
Training and accreditation for non-medical roles in the glaucoma care pathway 
Recommendations linking requirements for training and accreditation with specific roles in 
the glaucoma care pathway were first formally defined and published in the original NICE 
Glaucoma Guideline30.  CG 85 defined three levels of extended ‘permitted role’ beyond 
contemporaneous roles in glaucoma care provision for ophthalmic non-medical HCPs and 
provided general descriptors of key training requirements for each. These roles, by 
ascending case complexity, were: 
 
(i) Monitoring (but not treatment) of patients with OHT or suspected COAG with an 
established management plan. 
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(ii) Detection and diagnosis of OHT and glaucoma suspect status. 
(iii) Monitoring and treatment of patients with OHT, suspected COAG and COAG.  
 
The guideline listed role-specific clinical tests and assessments that HCPs should be trained 
in, both to perform and interpret, necessary to underpin clinical decision-making associated 
with the role. NICE recommendations explicitly stated that the roles be undertaken by 
trained HCPs, and that both specialist qualifications and experience were required for roles 
(ii) and (iii) when not working under consultant ophthalmologist supervision. The latter two 
roles were based largely upon content of the two levels of the CoO Glaucoma Higher 
Qualification (Certificates A and B) available at that time, although the language was used 
such that training and education were role specific and could be applied to any appropriate 
HCP.  
 
The concept of the NICE-defined extended roles for non-medical HCPs was developed 
further in the NICE-approved joint RCOphth and CCEHC Commissioning Guide: Glaucoma6. 
This document was designed “as a resource to assist commissioners, clinicians and 
managers to deliver high quality and evidence and outcome-based healthcare across 
England and beyond.” The scope covered detection and diagnosis in addition to 
management, and therefore formed a valuable reference source for those involved in 
service design. In the context of monitoring, the roles defined in the NICE guideline, and by 
association their related training and accreditation requirements, were assimilated into the 
Commissioning Guide. The three NICE-defined roles originally were incorporated as levels I, 
III and IV of the Commissioning Guide. The Guide used the (then recently updated) CoO 
Glaucoma Higher Qualifications as an example of accreditation required for each role, with 
levels I, III and IV being equivalent to Optometric core competence, CoO Glaucoma Higher 
Professional Certificate and Professional Diploma respectively.  An additional intermediate 
role, Level II, was added and recommended as a requirement for GERS, i.e. equivalent to the 
CoO Professional Certificate. The Commissioning Guide6 stated that whilst CoO Higher 
Qualifications were used as an illustrative example, other qualifications which quality-assure 
the same NICE5 CG85 levels of training would be equally acceptable.  
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In spite of the mapping of training and education and accreditation requirements with roles 
defined by both CG85 and the Commissioning Guide in 2015, access to training and 
accreditation remained limited to the three levels of CoO approved glaucoma higher 
qualifications. Publication of the OCCCF64 in 2016 aimed to support development of training 
and accreditation for HCPs from different professional backgrounds in four key areas of eye 
care delivery including glaucoma. This framework was authored jointly by the RCOphth, 
RCN, CoO, British and Irish Orthoptic Society (BIOS) and the Association of Health 
Professions in Ophthalmology (AHPO) as a series of documents, setting out specific 
competences “that ophthalmic non-medical HCPs need to possess in order to safely and 
successfully undertake the expanded roles that they are currently performing”.  The 
OCCCF64 was intended for use in development of education and training programmes with 
appropriate assessment processes.  To this end, sub-specialty areas included in the OCCCF 
were developed into curricula78, with supportive resources and assessment tools being 
made available online by Health Education England in 2019. The OCCCF defined three 
common levels of competence applied across the sub-specialties:  
 
(1) Ability to participate in triage/screening and to monitoring low risk patients with an 
established diagnosis to a clearly defined clinical protocol. 
(2) Ability to make preliminary diagnosis within a specific area and manage under specific 
protocols. 
(3) Ability to diagnose, manage and discharge within specific areas of practice.  
 
It is obvious that these three competence levels are matched and consistent with three 
roles described in both the NICE guideline30 and Commissioning Guide6. For each of the 
named sub-specialties, the framework defined competences that must be achieved at each 
level in ophthalmic history taking, examination, investigations, management and 
interventions, ability to deal with needs of patients, teaching and education, personal 
development. Helpfully, in the context of glaucoma, OCCCF publications clearly 
acknowledge that these framework levels were mapped to recognise existing training 
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programmes, giving again the example of the three levels of CoO Glaucoma Higher 
qualifications.  
Final points to note in relation to training and accreditation requirements within the 
glaucoma care pathway are: The NICE glaucoma update5, NG81, did not make changes to 
recommendations regarding roles and associated training and education requirements, but 
did remove the exception that NMPs working under supervision of a consultant 
ophthalmologist did not need to gain specialist accreditation relevant to their role; and 
furthermore, NG81 was careful to highlight the ‘holding an independent of non-medical 
prescribing qualification alone (without a specialist qualification relevant to the case 
complexity of glaucoma being managed) is insufficient for managing glaucoma or related 
conditions.’ 
 
Uncertainty on health economic issues in the care pathways 
There remains uncertainly about optimising care pathways within a wider health economics 
context.  Burr et al’s systematic review and economic evaluation of screening for open angle 
glaucoma79 concluded population based screening was not justified in the UK and case 
finding continues as the primary pathway for detection.  Interestingly in a recent editorial, 
Jonuscheit et al80 contrasted the GOS contract in Scotland with published evidence on 
primary community-based eye care services in England, albeit in a case comparison beyond 
that of glaucoma services alone. The authors argue that the Scottish GOS arrangements do 
provide value for money when compared with arrangements in England, concluding that the 
model provides enhanced ophthalmic services, free for all, permitting effective detection 
and management of acute eye conditions and improved quality of referrals to secondary 
care, albeit they concede knowledge gaps remain.   As is the case for GRFSs discussed 
above, there is a paucity of published work detailing health economic evaluations of 
community monitoring of glaucoma.  The realist review conducted by Baker et al3 noted 
that community glaucoma monitoring may be more expensive than if patients were 
monitored in the HES81,82, with factors contributing to higher community costs including 
equipment costs, shorter community monitoring intervals, high rates of re-referral back into 
the HES, and high opportunity costs to recover the lost income from the sale of spectacle. In 
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terms of this latter point, the business model of community optometry is highly dependent 
on the cross-subsidy from spectacle sales in order to ensure profitability.   
 
Setting aside the potential for debate about a hospital versus a community context for the 
care pathway, there are wider issues about sustainability of services and availability of 
resources to deliver care that some would argue might legitimately ‘trump’ economic 
matters for care providers; however, on an economic point, there is uncertainty about 
monitoring frequency, at least for OHT.  Burr et al’s evidence synthesis83,84 outlined that for 
confirmed OHT, monitoring more frequently than every 2 years was unlikely to be efficient 
and that while primary treatment and minimal monitoring (assessing IOP responsiveness to 
treatment) could be considered, further data via a cohort study was required on models for 
glaucoma risk prediction and patient preferences for treatment.  In so far as COAG is 
concerned, Boodhna and Crabb’s work85 has highlighted the potential benefits of stratifying 
patients to more or less monitoring based upon age and disease staging at diagnosis, 
although they too concede that further prospective evaluation is necessary. 
 
Developments in future care pathways 
It is clear that the detection and monitoring of glaucoma presents an enormous challenge.  
Considerable strides have been made to: improve efficiency of detection; increase capacity 
for review appointments; and introduce improved standardisation of the quality of care 
within monitoring services (with strong collaboration across primary and secondary care and 
multidisciplinary working being vital to such progress); however, it is clear that further 
progress is needed.  In terms of case finding, GRFS appear to work in terms of those seeking 
care but they do not reduce the burden of undetected disease or increase the equity of 
access to primary eye care.  Developments in Scotland are noteworthy in this regard.  In 
their paper arguing that aspects of the way the GOS Contract is implemented are contrary 
to the public health interest, Shickle et al86 suggest that the enhanced GOS model in 
Scotland should be judged by whether there is less of an incentive for community 
optometrists to cross-subsidise income through spectacle sales, thereby facilitating the 
opening of practices in more socioeconomically deprived areas.  Time will tell, although one 
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study examining practice distribution relative to deprivation has suggested that optometric 
practices in Scotland are relatively uniformly distributed across socioeconomic areas87. 
 
In terms of the clinical leadership of pathways for monitoring, there is as yet no guidance or 
consensus on the absolute numbers of glaucoma patients an individual consultant can 
reasonably take responsibility for.  The Way Forward report1 suggests that some units may 
have 6,000-8,000 patients per consultant, including non-medical HCP clinics, whilst in one 
region there was a solitary consultant covering a population of 80,000, a scenario deemed 
to be unsustainable. This issue may be an area for future debate, as the demand for 
glaucoma services increase and consultants are faced with the concomitant greater burden 
of responsibility for patient care with which they have less immediate control over. With a 
predicted increase in glaucoma cases of 22% over the next 10 years, current models 
dependent upon consultant supervision require a significant increase in consultant 
numbers, and/or for non-medical HCPs to take increasing responsibility for the care they 
deliver.  At the same time, the role of artificial intelligence (AI), while showing promise, does 
not offer immediate solutions.  In a recent review article on the use of AI in glaucoma, Zeng 
et al88 summarised that the techniques can successfully analyse and categorise data from 
measures of structure and function, ocular biomechanical properties, and a combination of 
these, in order to identify disease severity, determine disease progression, and/or 
recommend referral for specialised care.  While it seems almost certain that the care 
pathways of the future will employ AI, possibly in a variety of scenarios, the potential for 
clinical and cost-effectiveness requires further research to better determine the ways in 
which such technology can be effectively implemented to improve glaucoma care pathways. 
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